



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**


(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2017/12/07
 (87) Date publication PCT/PCT Publication Date: 2018/06/14
 (85) Entrée phase nationale/National Entry: 2019/05/28
 (86) N° demande PCT/PCT Application No.: EP 2017/081800
 (87) N° publication PCT/PCT Publication No.: 2018/104438
 (30) Priorités/Priorities: 2016/12/08 (US62/431,588);
 2016/12/08 (DE10 2016 123 847.3)

(51) Cl.Int./Int.Cl. *A61K 39/00* (2006.01),
C07K 14/47 (2006.01), *C07K 14/725* (2006.01)
 (71) Demandeur/Applicant:
 IMMATICS BIOTECHNOLOGIES GMBH, DE
 (72) Inventeurs/Inventors:
 ALTEN, LEONIE, DE;
 BUNK, SEBASTIAN, DE;
 MAURER, DOMINIK, DE;
 WAGNER, CLAUDIA, DE
 (74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : NOUVEAUX RECEPTEURS DE LYMPHOCYTES T ET IMMUNOTHERAPIE LES UTILISANT
 (54) Title: NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME

Figure 1:



(57) Abrégé/Abstract:

The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Figure 1:




Figure 2:




Figure 3:

R26P3H1




Figure 3




Figure 4:

R37P1C9




Figure 5:




Figure 6:

R42P3A9




Figure 7:




Figure 8:




Figure 9:




Figure 10:

R26P1A9




Figure 11:




Figure 12:




Figure 13:

R35P3A4




Figure 14:

R37P1C9




Figure 15:

R37P1H1




Figure 16:

R42P3A9




Figure 17:

R43P3F2




Figure 18:

R43P3G5





Figure 19:

Figure 21:



R26P1A9




Figure 22:




Figure 23:




Figure 24:




Figure 25:

R37P1C9




Figure 26:




Figure 27:




Figure 28:

R43P3F2




Figure 29:

R43P3G5




Figure 30:





Figure 31:

Figure 32:






Figure 33:

Figure 34:





Figure 35:






Figure 36:





Figure 37:

Figure 38:







Figure 39:

Figure 40:






Figure 41:




Figure 42:




Figure 43:




Figure 44:

Figure 1:

